The FINANCIAL — Alcon, the global leader in eye care and a division of Novartis, announces that the European Commission has approved Jetrea intravitreal injection (ocriplasmin) in the EU for the ...

Please provide your email address to receive an email when new articles are posted on . When managing myopic traction maculopathy, the timing of surgery should be carefully evaluated, avoiding early ...

FORT LAUDERDALE, Fla. — Myopic traction maculopathy, or MTM, is an evolving disease that requires different management at different stages. In the advanced stages, buckling leads to high rates of ...

Over the past two decades, the role of vitreomacular adhesion in vitreomacular interface pathologies, such as vitreomacular traction syndrome, epiretinal membrane and macular hole, has been ...

The composition of vitreous is 98% water and 2% structural macromolecules. Early in embryonic development, the molecular constituents of vitreous form a clear, gel-like structure that is adherent to ...

ThromboGenics NV and its partner, the Alcon unit of Novartis AG, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jetrea ...

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that the UK’s National Institute for Health and Care Excellence (NICE ...

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...

Advanced imaging technologies like intraoperative OCT and heads-up displays enhance surgical precision and patient outcomes ...